Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;7(4):180-183.
doi: 10.5152/eurjrheum.2020.20099.

Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome

Affiliations

Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome

Ayten Yazıcı. Eur J Rheumatol. 2020 Oct.

Abstract

Antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity with persistently positive antiphospholipid antibodies. However, in APS, there are several non-thrombotic clinical manifestations such as thrombocytopenia, cardiac valve disease, microthrombotic nephropathy, skin ulcer, or cognitive dysfunction. These non-criteria manifestations are relatively common and usually are non-responsive to anticoagulation. Among the non-criteria manifestations, thrombocytopenia, skin ulcers, migraine, and heart valve lesions are the most frequent manifestations described in APS. Limited data are available on the treatment of non-criteria manifestations of APS, and most therapeutic options are based on case reports or retrospective non-randomized studies. Although there is no consensus on the treatment of non-criteria manifestations of APS, anticoagulant therapy and immunomodulatory drugs could be combined in most patients.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The author has no conflict of interest to declare.

Similar articles

Cited by

References

    1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey L, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Throm Haemost. 2006;4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x. - DOI - PubMed
    1. Erkan D, Lockshin MD. Non-criteria manifestations of antiphospholipid syndrome. Lupus. 2010;19:424–7. doi: 10.1177/0961203309360545. - DOI - PubMed
    1. Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. Semin Arthritis Rheum. 2018;48:117–20. doi: 10.1016/j.semarthrit.2017.12.006. - DOI - PubMed
    1. Erkan D, Vega J, Ramon G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–71. doi: 10.1002/art.37759. - DOI - PubMed
    1. DiFrancesco LM, Burkart P, Hoehn JG. A cutaneous manifestation of antiphospholipid antibody syndrome. Ann Plast Surg. 2003;51:517–22. doi: 10.1097/01.SAP.0000058926.77448.9D. - DOI - PubMed

LinkOut - more resources